Inventiva S.A.

The current price of IVA is $3.63 — it has decreased by 6.20% since the previous close. Data as of Nov 5, 2026.

IVA is down 1.63% over the past week, up 4.91% over the past month and down 13.16% over the past year. The price is below its 200-day moving average of $4.85.

Analysts' average 12-month price target for IVA is $14.00, which implies 285.67% upside from the current price. Individual estimates range from $14.00 to $14.00.

Of the 12 analysts covering Inventiva S.A., 1 rates it a strong buy and 11 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

Inventiva S.A. has a market capitalization of $188.7M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, Inventiva S.A. posted a loss of $0.2841 per share against an estimate of -$0.20, missing expectations by 42.05%. Upcoming reports are listed in the earnings calendar.

Inventiva S.A. reported revenue of $22.73K in its most recent quarter, which has decreased by 99.56% compared with the same quarter a year earlier. Analysts had expected $2.88M.

Companies most comparable to Inventiva S.A. include Genfit S.A., Eupraxia Pharmaceuticals Inc., Avalo Therapeutics, Inc., Orchestra BioMed Holdings, Inc. and Enanta Pharmaceuticals, Inc.

In the latest trading session IVA moved between $3.62 and $3.96, a range of 9.37% of its current price.

Over the past 52 weeks IVA has traded between $2.82 and $7.29. The current price is 50.21% below its 52-week high.